MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.70704

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.

Erichsen Jennifer M, Register Thomas C, Sutphen Courtney, Ma Da, Gaussoin Sarah A, Rudolph Marc, Rundle Melissa, Bateman James T, Lockhart Samuel N, Sai Kiran K Solingapuram, Whitlow Christopher, Craft Suzanne

СтатьяРандомизированное исследованиеКлиническое исследование II фазыПеревод в очереди

Аннотация

INTRODUCTION

Agents targeting metabolic/vascular disorders are promising candidates to treat Alzheimer's disease (AD) and enhance safety and efficacy of other therapies.

METHODS

In a 2×2 factorial double-blinded randomized trial, participants with mild cognitive impairment (MCI), early AD, or who were amyloid positive received intranasal insulin (INI; 40 IU q.i.d.), the sodium-glucose cotransporter-2 inhibitor empagliflozin (10 mg q.d. oral tablet), both, or placebo for 4 weeks. The primary outcome was treatment-related adverse events (TRAEs). Secondary outcomes included the modified Preclinical Alzheimer's Cognitive Composite-5 (mPACC5), fluid biomarkers, cerebral blood flow (CBF), and fractional anisotropy (FA).

RESULTS

TRAEs were mild and similar for all groups. INI increased mPACC5, modulated FA and CBF, and reduced plasma glial fibrillary acidic protein. Empagliflozin lowered cerebrospinal fluid tau and modulated CBF. Both agents moderated immune/inflammatory/neurovascular markers.

DISCUSSION: INI and empagliflozin treatment was safe with promising effects on cognition, fluid, and imaging biomarkers. A longer and larger trial is needed to confirm these results.

CLINICAL TRIAL REGISTRATION: NCT05081219 HIGHLIGHTS: Agents targeting metabolic or vascular disorders are promising candidates to prevent or treat Alzheimer's disease (AD). Intranasal insulin and empagliflozin were safe alone or in combination for mild cognitive impairment/AD. Insulin improved cognition and markers of inflammation and immune function. Empagliflozin reduced markers of vascular injury and neurodegeneration. A longer, larger trial is needed to validate these results.

Для цитирования: Erichsen Jennifer M, Register Thomas C, Sutphen Courtney, Ma Da, Gaussoin Sarah A, Rudolph Marc, Rundle Melissa, Bateman James T, Lockhart Samuel N, Sai Kiran K Solingapuram, Whitlow Christopher, Craft Suzanne. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. DOI: 10.1002/alz.70704.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.